Neoantigen Peptide Vaccine

BIOLOGICAL4 trials

Sponsors

Washington University School of Medicine, Fred Hutchinson Cancer Center, Mayo Clinic, The First Affiliated Hospital of Nanchang University

Conditions

Advanced Malignant Solid TumorsAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast AdenocarcinomaCancer of the Pancreas

Phase 1

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

TerminatedNCT03956056

Washington University School of MedicineCancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer

Start: 2020-02-13End: 2023-07-06Updated: 2024-07-17

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

RecruitingNCT05098210

Fred Hutchinson Cancer CenterAnatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma +22

Start: 2022-06-09End: 2028-11-01Target: 28Updated: 2026-07-22

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

RecruitingNCT05269381

Mayo ClinicAnatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 +98

Start: 2022-03-31End: 2028-03-31Target: 138Updated: 2026-08-20

Unknown Phase

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

RecruitingNCT05749627

The First Affiliated Hospital of Nanchang UniversityAdvanced Malignant Solid Tumors

Start: 2023-04-01End: 2025-12-31Target: 20Updated: 2025-02-27

Related Papers

Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer

Science Advances2026-09-04

Abstract P3-10-16: Phase I/II of Personalized Neoantigen Peptide-Based Vaccine (PNeoVCA) in Combination with Pembrolizumab in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy

Clinical Cancer Research2025-06-131 citations

A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA).

Journal of Clinical Oncology2024-06-014 citations